DC in multiple myeloma immunotherapy.
Therapy for patients with multiple myeloma (MM) is currently unsatisfactory and most patients eventually succumb to relapsed disease. DCs are a subset of leukocytes with the capacity to initiate and control the adaptive immune response against many cancers, including MM. In MM patients, in vivo DC function is often abnormal, however, it appears that it can be restored by in vitro manipulation. This has led to the development of DC immunotherapy for MM patients. We review the background research leading to the recognition of an anti-MM immune response, and discuss abnormalities in DC function, potential tumor-associated Ags, and the results of clinical trials of DC immunotherapy in MM patients.
Turtle
C J
CJ
Dendritic Cell Laboratory, Mater Medical Research Institute, Raymond Terrace, South Brisbane, Queensland, Australia.
Brown
R D
RD
Joshua
D E
DE
Hart
D N J
DN
D017951:Antigen Presentation / Q000276:immunology; D015703:Antigens, CD / Q000276:immunology; D000951:Antigens, Neoplasm / Q000276:immunology; D019496:Cancer Vaccines / Q000627:therapeutic use*; D018929:Cell Culture Techniques / Q000379:methods; D002469:Cell Separation / Q000379:methods; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D016207:Cytokines / Q000276:immunology; D003713:Dendritic Cells / Q000276:immunology / Q000473:pathology* / Q000637:transplantation*; D006410:Hematopoiesis / Q000276:immunology; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D009101:Multiple Myeloma / Q000276:immunology / Q000473:pathology* / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology / Q000473:pathology
D015703:Antigens, CD; D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D016207:Cytokines